Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study.
Fiche publication
Date publication
octobre 2018
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier, Pr WESTEEL Virginie
Tous les auteurs :
Scherpereel A, Durand-Zaleski I, Cotté FE, Fernandes J, Debieuvre D, Blein C, Gaudin AF, Tournier C, Vainchtock A, Chauvin P, Souquet PJ, Westeel V, Chouaïd C
Lien Pubmed
Résumé
Territorial differences in the access to innovative anticancer drugs have been reported from many countries. The objectives of this study were to evaluate access to innovative treatments for metastatic lung cancer in France, and to assess whether socioeconomic indicators were predictors of access at the level of the municipality of residence.
Mots clés
France, Innovative treatments, Metastatic lung cancer, Social deprivation
Référence
BMC Cancer. 2018 Oct 22;18(1):1013